Financial Performance Overview
Lupin Limited reported exceptional financial results for FY 2025-26, demonstrating strong growth across key metrics. Consolidated revenue reached ₹279,580.3 million, representing a 23.1% year-over-year increase, while net profit surged 62.0% to ₹53,554.7 million. Standalone performance was equally impressive with revenue of ₹195,126.6 million (15% growth) and net profit of ₹63,665.6 million (60% growth). The US market contributed significantly with ₹116,783 million revenue (46% growth, 42% of global revenue), while India operations generated ₹81,140 million (7.1% growth, 30% of global revenue).
Dividend Declaration and AGM Details
The Board recommended a final dividend of ₹18 per equity share (900%) for FY26, subject to approval at the 44th Annual General Meeting scheduled for August 4, 2026. If approved, this will result in a cash outflow of approximately ₹8,229.2 million. The AGM will be conducted via video conference to approve FY26 financial statements, reappoint directors, and appoint Deloitte Haskins & Sells as statutory auditors for a 5-year term.
ESG and Sustainability Achievements
Lupin demonstrated outstanding environmental performance with a 41% reduction in Scope-1 and Scope-2 emissions from FY23 baseline and achieved 33% renewable electricity usage in India operations. The company maintained water-positive status for the fifth consecutive year with 45% water recyclability and sent 91% of incinerable hazardous waste for co-processing. Social initiatives reached 510,805 beneficiaries through CSR programs and 2.6 million patients through healthcare access initiatives. Lupin ranked #1 globally in the pharma sector by S&P Global with an ESG score of 91/100.
Strategic Business Moves and Restructuring
The company executed significant strategic transactions including the acquisition of diabetes brands Huminsulin from Eli Lilly for ₹4.64 billion and Gibtulio/Ajaduo from Boehringer Ingelheim for ₹3.28 billion. Business restructuring involved transferring the OTC division to Lupinlife Consumer Healthcare for ₹8.2 billion (resulting in ₹6.59 billion gain) and API R&D business to Lupin Manufacturing Solutions for ₹180 million (₹37.2 million gain).
Legal and Regulatory Matters
Lupin paid ₹4,232.9 million penalty for EU antitrust violation regarding Perindopril and maintained ₹856.1 million provision for ongoing disputes. The company faced income tax demands of ₹1,505.1 million and other contingent liabilities while maintaining strong compliance with SEBI regulations and corporate governance standards.
Employee Benefits and CSR
Employee benefit obligations increased substantially with gratuity liabilities at ₹6.0 billion and provident fund obligations at ₹15.5 billion. CSR expenditure was ₹547.7 million with ₹184.7 million shortfall, while MSME payables increased to ₹1.34 billion with ₹61.4 million interest due.
Governance and Risk Management
The company maintained a comprehensive Enterprise Risk Management framework aligned with ISO 31000 principles, addressing strategic risks including supply chain disruption, pricing pressure, and intellectual property protection. The Board composition included 10 directors (6 Independent, 3 Executive, 1 Non-Executive) with 30% women representation. Monthly ESG reviews were conducted by the Sustainability & CSR Committee chaired by Manju D. Gupta.
Outlook and Strategic Priorities
Lupin's forward strategy focuses on progressing SBTi-aligned decarbonization roadmap, expanding renewable energy adoption, enhancing water stewardship, strengthening climate risk integration, expanding healthcare access through digital platforms, and increasing women representation to 15% across workforce by 2030. The company continues to focus on complex generics and cost optimization while maintaining its position as the 3rd largest in US generics by prescriptions and 8th in Indian Pharmaceutical Market.